Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Acronis' Mid-Year Cyberthreats Report Reveals 464% Increase in Email Attacks 29-06-2023, 19:00

Stories that matter: applications for the Lorenzo Natali 14-03-2023, 15:40